Vertex Pharma stock pre-market at EUR 456.63
Published on 10/12/2026 at 08:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Vertex Pharma was at EUR 456.63 in pre-market trading at Lang & Schwarz.
- The bid was EUR 454.95 and the ask EUR 458.30.
- Vertex is scheduled to report third-quarter results on November 2, 2026.
Vertex Pharma stock was at EUR 456.63 at Lang & Schwarz at 8:02 a.m. CEST on October 12, 2026. The quote was recorded before the Xetra open.
Pre-market trading
Lang & Schwarz showed a bid of EUR 454.95 and an ask of EUR 458.30. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
What matters today
Vertex Pharmaceuticals is scheduled to report third-quarter 2026 results on November 2, 2026, after the market close, with its webcast set for 4:30 p.m. ET, according to the company's release. The next reported 52-week price level is EUR 560.25, which is 22.70 percent above the current quote. Structured market data showed a trailing P/E of 29.69 as of October 9, 2026.
Vertex also announced on October 9 that it had presented interim ALYFTREK data from a study of children ages 2 to 5 at the North American Cystic Fibrosis Conference, including data from 48 children in a PERT discontinuation substudy, in a company release.
Market context: Market report S&P 500.
